Pfizer establishes rare disease research unit

Section will address treating diseases affecting less than 200K people.

Pfizer has established 'Rare Disease Research Unit,' a new research unit to focus on the discovery of novel, life-saving medicines for rare diseases affecting less than 200,000 patients.

Pfizer's 'Rare Disease Research Unit' is expected to pursue treatments across all therapeutic areas and will serve as the focal point for the company's existing research on rare diseases.

Further, Pfizer plans to work closely with patient advocacy groups as it develops and advances the unit's research strategy.

The 'Rare Diseases Research Unit' will be lead by Edward Mascioli. He was the founder and CEO of Dapis Capital, a private equity firm focused on healthcare and the life sciences.

Jose Carlos Gutierrez-Ramos, senior vice president of BioTherapeutics Research and Development, said: "We are very excited about our new Rare Diseases Research Unit. We are coupling Pfizer's existing experience in rare diseases, such as haemophilia, with our advanced protein technologies, resources and scientific team to focus on becoming a driving force in rare disease research."